{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=50&q=metastatic+pancreatic", "query": { "q": "metastatic pancreatic", "condition": "Pancreatic Cancer", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 1135, "total_pages": 114, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=51&q=metastatic+pancreatic&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Cancer&page=49&q=metastatic+pancreatic&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T20:57:24.083Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03563144", "title": "QUILT-3.088: NANT Pancreatic Cancer Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Aldoxorubicin HCl", "type": "DRUG" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-08", "completion_date": "2022-02-09", "has_results": false, "last_update_posted_date": "2025-02-21", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563144" }, { "nct_id": "NCT05254171", "title": "Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Cancer Metastatic", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer Stage IV" ], "interventions": [ { "name": "SBP-101", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Panbela Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2022-08-08", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 14, "location_summary": "Hot Springs, Arkansas • Fullerton, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05254171" }, { "nct_id": "NCT03291938", "title": "IACS-010759 in Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Malignant Solid Neoplasm", "Pancreatic Ductal Adenocarcinoma", "Progesterone Receptor Negative", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Lymphoma", "Refractory Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage IIA Pancreatic Cancer AJCC v8", "Stage IIB Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Oxidative Phosphorylation Inhibitor IACS-010759", "type": "DRUG" }, { "name": "Pharmacodynamic Study", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2017-11-13", "completion_date": "2020-11-23", "has_results": false, "last_update_posted_date": "2020-11-24", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291938" }, { "nct_id": "NCT02562898", "title": "Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Margaret Tempero", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-10-12", "completion_date": "2020-09-01", "has_results": true, "last_update_posted_date": "2021-05-06", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 2, "location_summary": "San Francisco, California • Portland, Oregon", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02562898" }, { "nct_id": "NCT07219238", "title": "Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colorectal Cancer", "Gastric Cancers", "Ovarian Cancers", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2026-10", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 1, "location_summary": "Grand Rapids, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07219238" }, { "nct_id": "NCT02048384", "title": "A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "metformin alone (Arm A)", "type": "DRUG" }, { "name": "metformin (Arm B)", "type": "DRUG" }, { "name": "rapamycin (Arm B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-06-10", "completion_date": "2019-09", "has_results": false, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Baltimore, Maryland", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02048384" }, { "nct_id": "NCT00569387", "title": "Vaccine Study for Surgically Resected Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "HyperAcute(R)-Pancreatic Cancer Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2007-12", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Orange, California + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569387" }, { "nct_id": "NCT06818812", "title": "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB186748", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "GEMNabP", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-03-27", "completion_date": "2027-03-27", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 9, "location_summary": "Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06818812" }, { "nct_id": "NCT01632306", "title": "A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "LY2090314", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2013-03", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2019-01-15", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01632306" }, { "nct_id": "NCT05360732", "title": "Redefining FOLFIORINOX in Older Pancreatic Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 37, "start_date": "2022-04-22", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-17T20:57:24.083Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05360732" } ] }